Advances and challenges in the treatment of esophageal cancer
Esophageal cancer (EC) is one of the most common cancers with high morbidity and mortality rates. EC includes two histological subtypes, namely esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC primarily occurs in East Asia, whereas EAC occurs in Western countries....
Main Authors: | Shiming He, Jian Xu, Xiujun Liu, Yongsu Zhen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-11-01
|
Series: | Acta Pharmaceutica Sinica B |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383521000794 |
Similar Items
-
Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles
by: Qingxia Fu, et al.
Published: (2020-01-01) -
Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?
by: Hannah Christina Puhr, et al.
Published: (2021-09-01) -
Comparative transcriptome characterization of esophageal squamous cell carcinoma and adenocarcinoma
by: Xianfeng Li, et al.
Published: (2023-01-01) -
The Changing Face of Esophageal Cancer
by: Rachel E. Melhado, et al.
Published: (2010-06-01) -
Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?
by: Shayan Khalafi, et al.
Published: (2020-10-01)